Introduction
21 CFR Part 812 is a crucial regulatory framework that governs clinical investigations involving investigational devices. It outlines the responsibilities of sponsors, investigators, and institutional review boards (IRBs) to ensure the safety and efficacy of the devices under study. This article provides an in-depth overview of the key components of 21 CFR Part 812, including the purpose and scope of the regulation, the IDE application and approval process, the differences between significant risk and nonsignificant risk devices, exemptions from IDE requirements, labeling and distribution requirements, informed consent and subject protection, monitoring and reporting responsibilities, quality management systems (QMS) and compliance, as well as common challenges and best practices for IDE compliance.
By understanding and adhering to these regulations, sponsors and investigators can conduct clinical investigations that prioritize patient safety and contribute to the advancement of medical science.
What is 21 CFR Part 812?
21 CFR Part 812 covers the regulatory structure necessary for the supervision of involving investigational equipment. It outlines the duties and necessary processes for sponsors, investigators, and institutional review boards (IRBs) to ensure the safety and effectiveness of the equipment being studied. The section specifies thorough explanations vital to the regulatory process, such as ‘restricted object,’ which pertains to any item with imposed limitations on sale, distribution, or use as mandated by specific regulations set forth under the Federal Food, Drug, and Cosmetic Act. Moreover, it establishes ‘,’ which the FDA employs to classify appliances, and ‘product code,’ a distinctive identifier for appliance categorization. It also outlines what constitutes ‘representative sampling’ of advertisements and labeling, providing guidance on the promotional material that conveys the product’s claims. Impoftantly, the regulation covers ” that may impact the identity of the effectiveness and profile of a product, such as changes to the label, components, intended purpose, contraindications, or usage guidelines.
The initial importer plays a crucial role in the supply chain, being the first point of contact within the U.S. for an item entering from abroad, without altering the item’s original packaging or labeling. The by confirming the safety, effectiveness, and security of . This is embodied in their rigorous oversight of the nation’s food supply, pharmaceuticals, and other health-related products. To safeguard the integrity of treatments for rare conditions, designations are used to identify drugs meant for rare diseases or subsets within non-rare conditions, respectively. These designations are crucial as they come with exclusive approval rights that encourage the development of therapies for rare diseases by ensuring market exclusivity for a period post-approval. The standards for determining whether a subsequent product is the same as a previously approved one is rigorous, taking into account factors such as molecular structure and superiority.
Purpose and Scope of 21 CFR Part 812
‘ is crucial to the regulation of investigational devices, outlining the responsibilities and guidelines for sponsors, investigators, and Institutional Review Boards (IRBs). Within its framework, sponsors are required to submit an (IDE) application, a pivotal step before commencing . This regulation meticulously outlines the , including the need for representative samples of advertisements and any other labeling to reflect the promotional claims made for the product accurately. Furthermore, any significant alterations in the labeling or advertising of the product, which may affect its identity or safety and efficacy, must be reported.
The regulation also emphasizes the importance of the classification name, which describes a device or class of devices, and the product code, which the FDA uses to identify a device’s generic category. These elements are essential for preserving the integrity and compliance of investigations in the medical field. The scope of Part 812 spans the entire clinical investigation continuum, from the initial IDE application to the final reporting of study results, encompassing all stages to ensure the protection and well-being of human subjects.
The is to , among other responsibilities. As such, the agency has recently updated its standards for direct-to-consumer prescription drug advertisements to ensure clear, conspicuous, and neutral presentation of major side effects and contraindications in TV and radio formats, echoing the principles of transparency and patient well-being that underpin .
It is important to mention that the FDA’s supervision of medical product safety, which includes , is a high-priority matter. Research has brought attention to the possible connection between and a substantial amount of harm and fatalities, emphasizing the crucial requirement for strict regulatory frameworks such as . The regulation serves as a foundation to safeguard subjects in investigations, ensuring that the potential benefits to subjects and the value of the knowledge to be gained justify the risks involved.
Key Components of 21 CFR Part 812
The complexities of are crucial for research professionals in the field of investigation, covering a range of components that establish the basis of studies on experimental tools. Commencing with the description of a research instrument, these regulations outline the requirements for acquiring an (IDE), which allows a medical instrument to be employed in a study to gather data on well-being and efficacy. The procedures for conducting the investigation are methodically outlined, ensuring that the study design adheres to the highest scientific standards.
Moreover, the regulation delineates the respective responsibilities of sponsors, investigators, and , creating a framework for accountability and oversight. The is particularly emphasized, requiring clear communication to participants about the risks and benefits of the study. Additionally, the maintenance of meticulous records and the submission of accurate reports are mandated to uphold the integrity of the trial and to ensure compliance with .
Recent FDA updates further underscore the importance of presenting drug information in a clear, conspicuous, and neutral manner, as seen in the “Direct-to-Consumer Prescription Drug Advertisements” rule. This reflects an overarching commitment to , which resonates throughout . The FDA’s responsibility in protecting public health by guaranteeing the safety and efficiency of medical equipment is crucial to these regulatory elements, which as a whole direct the ethical and scientific behavior of trials.
IDE Application and Approval Process
Navigating the complexities of an application under is crucial for trial sponsors and investigators. An IDE application is a comprehensive file that includes details ranging from the description of the apparatus, manufacturing information, to the proposed study protocol. The FDA’s role goes beyond evaluating the safety and efficacy of medical devices; it also involves assessing the application’s adherence to robust crucial for the reliability and scalability of biomedical tools in the context of trials.
For example, an IDE application for an investigation that seeks to alter health policies or standards of care must present comprehensive evidence. This includes with annual direct costs exceeding $700,000, underlining the financial magnitude and implications of such research. The FDA review process is stringent, with the agency granting under section 526 of the act, ensuring seven years of market exclusivity, barring any clinically superior subsequent drugs.
In the realm of medical equipment, coverage and payment decisions by payors after can be influenced by the data manufacturers submit to demonstrate a product’s safety and effectiveness. Given that this information may not meet the criteria of payors, it could result in delays or denials in the availability of the product.
Chris, a biomedical engineer with vast experience in overseeing studies for Class III equipment, emphasizes the significance of adjusting and updating software tools to harness new technologies and computing models – a hurdle often encountered due to resource constraints. This echoes the FDA’s initiative in emphasizing the need for reliable and efficient software tools, a sentiment that is increasingly shared among stakeholders in the field.
To this end, the eCFR’s published edition presents information in an indented format for user convenience, ensuring clarity in the interpretation of regulatory documents. These insights are crucial for sponsors and investigators to understand the IDE application process, positioning them to effectively initiate and conduct their investigations.
Differences Between Significant Risk and Nonsignificant Risk Devices
Under the jurisdiction of 21 CFR Part 812, are thoroughly categorized based on the level of risk they pose to participants in a . Devices are categorized as either (SR) or (NSR), and this distinction is pivotal in determining the extent of required. For objects considered to be of notable risk, strict supervisory measures are in place to safeguard participant well-being, while those evaluated as in are subject to less rigorous regulatory controls. The criteria for this risk classification encompass a range of factors, including the intended use of the device, its technological complexity, and the potential for harm. Sponsors and investigators must be skilled at distinguishing these classifications to ensure their research adheres to the appropriate and upholds the highest safety protocols for trial participants.
Exemptions from IDE Requirements
To ensure the swift and compliant progression of , it is imperative to recognize instances where an may not be a requisite under 21 CFR Part 812. For instance, the Impella Connect System, which includes a web-based portal and hardware for in critical care, is classified as an item necessitating due to its life-critical alarm functions. Likewise, exceptions are given to authorized professionals who produce or alter instruments exclusively for their profession, retail stores such as pharmacies that provide instruments directly to customers, and organizations engaged in producing instruments solely for research, education, or analysis with no commercial distribution. Moreover, carriers engaged in the regular conduct of business and service providers who distribute products to the end user are exempt. These exemptions are essential for sponsors and investigators to navigate, as they provide clarity on when an IDE is not mandatory, thereby streamlining the initiation of without compromising on .
Labeling and Distribution Requirements
for , as mandated by 21 CFR Part 812, are fundamental to maintaining compliance with . Labels must clearly convey essential information, such as the classification name, product code, and any restrictions on sale, distribution, or use as per FDA guidelines. This guarantees that are accurately identified and that their are not compromised by improper labeling.
Essential information, including promotional claims made for the product, must be represented in a ‘representative sampling of advertisements’ and any other labeling materials. These should exclude labels and package inserts but provide accurate depictions of the claims. Additionally, any or advertisements that may impact the product’s identity or performance must be recorded and evaluated for conformity.
Sponsors and initial importers have specific . Initial importers, who introduce an item from a foreign manufacturer to the U.S. market, must ensure they do not alter the packaging or labeling in a way that might affect compliance. Furthermore, they must report any event related to the manufacturing process of the equipment, such as deviations from good manufacturing practices or unforeseen circumstances that could affect the device’s integrity, purity, or effectiveness.
Recent case studies illustrate the gravity of these requirements. For example, a firm’s response to FDA’s inquiry about complaint coding and quality data analysis was deemed inadequate due to the absence of outcomes from their corrective actions. This highlights the need for and evidence of compliance.
Furthermore, the FDA’s responsibility in safeguarding public health by ensuring the of medical equipment serves as a reminder of the significance of strict compliance with labeling and distribution regulations. Every party involved in the process, from the sponsor to the investigator, must understand their responsibilities to ensure the proper handling and use of investigational devices throughout the investigation.
The ethical foundation of medical research is deeply rooted in the principle of , as delineated in . This crucial process involves a comprehensive dialogue between researchers and participants, ensuring individuals are fully apprised of the study’s purpose, potential risks, benefits, and procedures. The form must encapsulate this information in a manner that is both clear and concise to support participants’ understanding of their involvement. The safeguarding of is paramount, and is integral to uphold this standard. The recent attention to in research has highlighted key aspects that need to be conveyed at the onset, such as study length and any pertinent information that aids participants in making an informed decision. This is in line with the fundamental tenets of the and the draft guidance issued by the FDA, which both underscore the significance of communicating the essence of the research in an accessible format. Moreover, the inclusion of key details in consent documents not only benefits potential participants but also serves as a valuable tool for those already involved in the study. The responsibility of conveying this information effectively falls upon sponsors, investigators, and IRBs, who must navigate these requirements with precision and care.
Monitoring and Reporting Responsibilities
Following the Code of Federal Regulations (CFR) Title 21 Part 812 is crucial for the well-being and integrity of investigations. This section outlines the for sponsors and investigators that are critical for maintaining compliance with these regulations. Responsibilities include meticulous data collection, prompt , and regular study progress reporting. Precise monitoring ensures that any deviation from the , applicable regulations, standards, or specifications that may impact the well-being, purity, or potency of a product is reported. This applies to events occurring not only within the sponsor’s facility but also at any contracted facility.
The in overseeing the conduct of trials to protect public health. For instance, the FDA recently established standards ensuring that direct-to-consumer prescription drug advertisements present major side effects and contraindications clearly and neutrally. This reflects the agency’s commitment to transparency and security in all aspects of drug marketing, which aligns with the monitoring and reporting ethos in .
In the event of a , a comprehensive response plan, including public warnings and checks for effectiveness, must be implemented. The plan must detail the actions to be taken by the entity under a cease distribution and notification order or a mandatory recall order. This includes all necessary corrections, such as repair, modification, adjustment, relabeling, destruction, or inspection of the object without its physical removal from the point of use.
For health professionals engaged in clinical investigations, understanding the nuances of these regulations, such as the definitions of ‘consignee,’ ‘correction,’ ‘device user facility,’ and ‘restricted device,’ is of paramount importance. These terms outline who is responsible for the handling of medical equipment and the scope of their responsibilities. For example, ‘initial importer’ refers to any importer who furthers the marketing of a device to the final point of sale but does not alter the device’s packaging or labeling.
The CFR also provides clarity on , ensuring that newly approved drugs for rare diseases are protected from competition for a specific period, fostering innovation and research in this critical area.
It is crucial for sponsors and investigators to stay informed about these regulatory requirements to ensure the continued safety of trials and adherence to high standards of practice.
Quality Management System (QMS) and Compliance
A robust is pivotal in meeting the compliance requirements of . At the core of a QMS are the , which provide a blueprint for conducting operations in a consistent and compliant manner. Essential to the integrity of the QMS, SOPs need to be well-documented and accessible, ensuring that all team members are informed and can perform their duties according to the established protocols.
are another cornerstone of a comprehensive QMS. They ensure that all personnel are equipped with the necessary knowledge and skills to maintain compliance with the changing landscape of trial regulations. By promoting a culture of continuous learning, organizations can better handle the risks associated with medical instrument development and .
Document control systems serve as the repository for all QMS documentation, ensuring that the most current procedures are used and that historical data is preserved for reference or audits. This careful method of recording information is not just a legal obligation but also a recommended approach that improves the effectiveness and efficiency of medical equipment.
Quality audits, both internal and external, are indispensable for verifying compliance with regulatory standards and identifying areas for improvement. Audits offer an opportunity for organizations to scrutinize their processes and make necessary adjustments to uphold the highest quality standards.
Furthermore, fostering a culture of compliance within the organization is not only about following regulations; it’s about instilling a mindset where quality and patient well-being are paramount. plays a critical role in this context by ensuring that all aspects of the QMS align with regulatory expectations and contribute to the delivery of high-quality medical instruments.
The integration of , as highlighted by Etienne Nichols, a Medical Device Guru, into the QMS fortifies the commitment to patient safety and product excellence. Adherence to standards such as ISO 14971 complements the QMS by providing a framework for risk assessment and mitigation throughout the device lifecycle.
In light of the public nature of comments and submissions to the FDA, as emphasized in recent FDA communications, it is incumbent upon organizations to be vigilant about the confidentiality of their submissions. This extends to maintaining the privacy of sensitive information within the QMS and being responsible for the data shared in regulatory interactions.
By comprehending the complexities of and incorporating these crucial elements into their QMS, sponsors, investigators, and research organizations can guarantee that their activities not only adhere to regulations but are also positioned to improve patient outcomes and contribute to the progress of medical science.
Common Challenges and Best Practices for IDE Compliance
Ensuring adherence to the presents a multifaceted challenge, akin to the stringent compliance needs seen in the banking sector and advanced IT companies. In the field of medical investigations, issues range from intricately designed studies to precise patient recruitment strategies, rigorous data management, and meticulous . To navigate these complexities, sponsors and investigators must adopt that mirror the commitment to excellence demonstrated by organizations such as M&T Bank in , or Scieneers with their robust data engineering services. For instance, adopting stringent Clean Code standards and leveraging advanced features of IDEs, like the comprehensive refactoring capability of PyCharm, can lead to improved study maintainability and reliability. Furthermore, in line with the FDA’s focus on clear, conspicuous, and neutral communication of prescription drug information, trials must present data and regulatory submissions with equal clarity and neutrality to foster trust and ensure compliance. By integrating such , sponsors and investigators can significantly improve their prospects for successful , akin to how software standards safeguard the highly sensitive data in banking. This structured approach to not only aligns with the FDA’s public health mission but also upholds the integrity of clinical research in the quest for medical advancements.
Conclusion
In conclusion, 21 CFR Part 812 is a crucial regulatory framework governing clinical investigations involving investigational devices. It outlines the responsibilities of sponsors, investigators, and institutional review boards (IRBs) to ensure device safety and efficacy.
Key components of 21 CFR Part 812 include the IDE application and approval process, differences between significant risk and nonsignificant risk devices, exemptions from IDE requirements, labeling and distribution protocols, informed consent and subject protection, monitoring and reporting responsibilities, and quality management systems (QMS) and compliance.
Compliance with these regulations is essential for conducting safe and effective clinical investigations. Understanding IDE applications, adhering to labeling and distribution requirements, and prioritizing informed consent and subject protection are crucial. Additionally, maintaining rigorous monitoring and reporting practices, implementing a robust QMS, and adopting best practices enhance compliance and contribute to the advancement of medical science.
By adhering to 21 CFR Part 812, sponsors and investigators can conduct clinical investigations that prioritize patient safety and contribute to medical advancements. These regulations provide a framework for ethical and scientific conduct in clinical trials, ensuring the safety of participants and the integrity of the research process.
In summary, understanding and adhering to the key components of 21 CFR Part 812 are essential for sponsors and investigators to conduct compliant and ethical clinical investigations. By prioritizing patient safety and adhering to these regulations, stakeholders can contribute to the advancement of medical science and improve patient outcomes.
Learn how bioaccess™ can assist you in conducting compliant and ethical clinical investigations in Latin America.
Frequently Asked Questions
What is 21 CFR Part 812?
21 CFR Part 812 is a regulation that outlines the requirements and responsibilities for sponsors, investigators, and institutional review boards (IRBs) involved in clinical investigations of investigational devices. Its primary aim is to ensure the safety and effectiveness of the equipment being studied.
What does the term ‘restricted object’ mean in this context?
A ‘restricted object’ refers to any item that has limitations on its sale, distribution, or use, as mandated by specific regulations under the Federal Food, Drug, and Cosmetic Act.
How does the FDA classify devices?
The FDA classifies devices using a ‘classification name’ that describes the device or class of devices, along with a ‘product code,’ which serves as a unique identifier for categorization.
What is the importance of representative sampling in advertisements and labeling?
Representative sampling refers to the requirement that promotional materials accurately reflect the claims made for the product. It ensures that advertisements are truthful and not misleading.
What constitutes a ‘significant modification’ under these regulations?
Significant modifications can include changes to a product’s label, components, intended purpose, contraindications, or usage guidelines that may affect the identity or effectiveness of the product.
What role does the initial importer play in the regulatory process?
The initial importer is the first point of contact in the U.S. for an item that enters from abroad. They must ensure that the item’s original packaging or labeling is not altered and report any manufacturing process-related events that may impact the device’s integrity.
What are orphan drug designations?
Orphan drug designations are used for drugs intended for rare diseases. They provide exclusive approval rights and market exclusivity for a specific period post-approval to encourage the development of therapies for rare conditions.
What is an Investigational Device Exemption (IDE)?
An IDE is a submission required from sponsors to allow the use of an investigational device in a clinical study. It includes details about the device, manufacturing information, and the proposed study protocol.
How does 21 CFR Part 812 ensure the protection of human subjects?
The regulation emphasizes informed consent, requiring clear communication of the study’s purpose, potential risks, and benefits to participants. Sponsors and investigators are responsible for upholding the integrity of informed consent throughout the study.
What monitoring requirements are specified under this regulation?
Sponsors and investigators must collect data meticulously, report adverse events promptly, and provide regular study progress updates to ensure compliance with the regulations and the well-being of participants.
What responsibilities do sponsors and investigators have regarding labeling and distribution?
They must ensure that labels accurately convey essential information, including the classification name and product code, and that any significant alterations in labeling or advertisements are documented and evaluated for compliance.
What is the significance of a Quality Management System (QMS) in this context?
A QMS is essential for maintaining compliance with 21 CFR Part 812. It includes Standard Operating Procedures (SOPs), training programs, document control systems, and quality audits to ensure that all processes align with regulatory expectations.
How are risk levels classified for investigational medical instruments?
Investigational medical instruments are categorized as either significant risk (SR) or non-significant risk (NSR). This classification determines the level of regulatory oversight required during clinical studies.
Are there instances where an IDE is not required?
Yes, exceptions exist for certain situations, such as authorized professionals producing instruments solely for their profession or organizations that create instruments exclusively for research or education without commercial distribution.
What recent updates from the FDA relate to clinical investigations?
The FDA has updated standards for direct-to-consumer prescription drug advertisements, emphasizing the need for clear and neutral presentation of major side effects and contraindications, which aligns with the principles of transparency in clinical investigations.
List of Sources
- What is 21 CFR Part 812?
- ecfr.gov (https://ecfr.gov/current/title-21/chapter-I/subchapter-H/part-807/subpart-A)
- fda.gov (https://fda.gov/news-events/press-announcements/fda-roundup-march-22-2024)
- fda.gov (https://fda.gov/news-events/press-announcements/fda-roundup-november-21-2023)
- fda.gov (https://fda.gov/news-events/press-announcements/fda-roundup-october-20-2023)
- ecfr.gov (https://ecfr.gov/current/title-21/chapter-I/subchapter-D/part-316/subpart-A)
- fda.gov (https://fda.gov/medical-devices/premarket-submissions-selecting-and-preparing-correct-submission/division-standards-and-conformity-assessment)
- Purpose and Scope of 21 CFR Part 812
- ecfr.gov (https://ecfr.gov/current/title-21/chapter-I/subchapter-H/part-807/subpart-A)
- gao.gov (https://gao.gov/products/gao-24-106699?utm_medium=social&utm_source=twitter&utm_campaign=usgao)
- ecfr.gov (https://ecfr.gov/current/title-21/chapter-I/subchapter-H/part-812/subpart-B/section-812.30)
- fda.gov (https://fda.gov/news-events/press-announcements/fda-roundup-november-21-2023)
- fda.gov (https://fda.gov/news-events/press-announcements/fda-roundup-september-6-2024)
- Key Components of 21 CFR Part 812
- ecfr.gov (https://ecfr.gov/current/title-21/chapter-I/subchapter-H/part-812/subpart-B/section-812.30)
- ecfr.gov (https://ecfr.gov/current/title-21/chapter-I/subchapter-D/part-316/subpart-A)
- ecfr.gov (https://ecfr.gov/current/title-21/chapter-I/subchapter-H/part-878)
- fda.gov (https://fda.gov/news-events/press-announcements/fda-roundup-september-6-2024)
- fda.gov (https://fda.gov/news-events/press-announcements/fda-roundup-november-21-2023)
- ecfr.gov (https://ecfr.gov/current/title-21/chapter-I/subchapter-H/part-807/subpart-A)
- ecfr.gov (https://ecfr.gov/current/title-21/chapter-I/subchapter-H/part-807/subpart-A)
- IDE Application and Approval Process
- grants.nih.gov (https://grants.nih.gov/grants/guide/pa-files/PAR-24-050.html?utm_source=dlvr.it&utm_medium=twitter)
- grants.nih.gov (https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-24-010.html?utm_source=dlvr.it&utm_medium=twitter)
- ecfr.gov (https://ecfr.gov/current/title-21/chapter-I/subchapter-E/part-514/subpart-B/section-514.115)
- fda.gov (https://fda.gov/about-fda/cdrh-innovation/medical-device-coverage-initiatives-connecting-payors-payor-communication-task-force)
- ecfr.gov (https://ecfr.gov/current/title-21/chapter-I/subchapter-D/part-316/subpart-A)
- greenlight.guru (https://greenlight.guru/blog/data-management-and-reporting-in-fda-regulated-clinical-trials)
- greenlight.guru (https://greenlight.guru/blog/how-to-set-up-clinical-studies-to-comply-with-us-fda-regulations)
- greenlight.guru (https://greenlight.guru/blog/strategies-for-successful-pma-submissions-a-guide-for-clinical-teams)
- federalregister.gov (https://federalregister.gov/documents/2023/10/19/2023-23110/enforcement-policy-for-non-invasive-remote-monitoring-devices-used-to-support-patient-monitoring)
- fda.gov (https://fda.gov/about-fda/cdrh-innovation/medical-device-coverage-initiatives-connecting-payors-payor-communication-task-force)
- Differences Between Significant Risk and Nonsignificant Risk Devices
- fda.gov (https://fda.gov/news-events/press-announcements/fda-roundup-november-21-2023)
- fda.gov (https://fda.gov/news-events/press-announcements/fda-proposes-rule-aimed-helping-ensure-safety-and-effectiveness-laboratory-developed-tests)
- ecfr.gov (https://ecfr.gov/current/title-21/chapter-I/subchapter-H/part-807/subpart-A)
- statnews.com (https://statnews.com/2024/09/16/cardiovascular-medical-devices-safety-recall-fda-510k-pathway?utm_campaign=rss)
- fda.gov (https://fda.gov/medical-devices/safety-communications/hintermann-series-h3-total-ankle-replacement-has-higher-expected-risk-device-failure-fda-safety)
- federalregister.gov (https://federalregister.gov/documents/2023/12/21/2023-27935/institutional-review-board-waiver-or-alteration-of-informed-consent-for-minimal-risk-clinical)
- ecfr.gov (https://ecfr.gov/current/title-21/chapter-I/subchapter-H/part-878)
- Exemptions from IDE Requirements
- ecfr.gov (https://ecfr.gov/current/title-21/chapter-I/subchapter-H/part-807/subpart-A)
- fda.gov (https://fda.gov/news-events/press-announcements/fda-roundup-november-21-2023)
- fda.gov (https://fda.gov/news-events/press-announcements/fda-roundup-october-20-2023)
- fda.gov (https://fda.gov/news-events/press-announcements/fda-roundup-september-6-2024)
- fda.gov (https://fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/abiomed-inc-663150-09192023)
- ecfr.gov (https://ecfr.gov/current/title-21/chapter-I/subchapter-H/part-807/subpart-D)
- federalregister.gov (https://federalregister.gov/documents/2023/11/03/2023-24290/medical-devices-exemptions-from-premarket-notification-class-ii-devices-clinical-electronic)
- Labeling and Distribution Requirements
- ecfr.gov (https://ecfr.gov/current/title-21/chapter-I/subchapter-H/part-807/subpart-A)
- fda.gov (https://fda.gov/news-events/press-announcements/fda-roundup-november-21-2023)
- fda.gov (https://fda.gov/news-events/press-announcements/fda-roundup-october-20-2023)
- fda.gov (https://fda.gov/news-events/press-announcements/fda-roundup-march-15-2024)
- fda.gov (https://fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/abiomed-inc-663150-09192023)
- fda.gov (https://fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/exactech-inc-669904-01192024)
- fda.gov (https://fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/wavi-co-658549-10202023)
- ecfr.gov (https://ecfr.gov/current/title-21/chapter-I/subchapter-F/part-600/subpart-B/section-600.14)
- ecfr.gov (https://ecfr.gov/current/title-21/chapter-I/subchapter-H/part-807/subpart-A)
- Informed Consent and Subject Protection
- jamanetwork.com (https://jamanetwork.com/journals/jama/article-abstract/2820280)
- FDA Works to Make Informed Consent Easier to Understand (https://fda.gov/news-events/fda-voices/fda-works-make-informed-consent-easier-understand)
- ecfr.gov (https://ecfr.gov/current/title-21/chapter-I/subchapter-D/part-316/subpart-A)
- federalregister.gov (https://federalregister.gov/documents/2024/03/01/2024-04377/key-information-and-facilitating-understanding-in-informed-consent-draft-guidance-for-sponsors)
- researchamerica.org (https://researchamerica.org/press-releases-statements/large-majority-of-americans-say-consideration-of-clinical-trial-participation-should-be-a-part-of-regular-health-care)
- peoplespharmacy.com (https://peoplespharmacy.com/articles/how-informed-are-patients-who-sign-consent-forms)
- FDA Works to Make Informed Consent Easier to Understand (https://fda.gov/news-events/fda-voices/fda-works-make-informed-consent-easier-understand)
- Monitoring and Reporting Responsibilities
- ecfr.gov (https://ecfr.gov/current/title-21/chapter-I/subchapter-H/part-807/subpart-A)
- ecfr.gov (https://ecfr.gov/current/title-21/chapter-I/subchapter-F/part-600/subpart-B/section-600.14)
- fda.gov (https://fda.gov/news-events/press-announcements/fda-roundup-november-21-2023)
- federalregister.gov (https://federalregister.gov/public-inspection/2024-20814/public-health-service-policies-on-research-misconduct)
- ecfr.gov (https://ecfr.gov/current/title-21/chapter-I/subchapter-H/part-810)
- ecfr.gov (https://ecfr.gov/current/title-21/chapter-I/subchapter-D/part-316/subpart-A)
- ecfr.gov (https://ecfr.gov/current/title-21/chapter-I/subchapter-E/part-514/subpart-B/section-514.87)
- hitconsultant.net (https://hitconsultant.net/2023/11/21/clinical-trial-data-strategy-shifting-to-innovative-data-collection)
- fda.gov (https://fda.gov/regulatory-information/search-fda-guidance-documents/use-data-monitoring-committees-clinical-trials?utm_content=bufferf9e54&utm_medium=social&utm_source=twitter.com&utm_campaign=buffer)
- Quality Management System (QMS) and Compliance
- ecfr.gov (https://ecfr.gov/current/title-21/chapter-I/subchapter-H/part-807/subpart-A)
- ecfr.gov (https://ecfr.gov/current/title-21/chapter-I/subchapter-H/part-820/subpart-A/section-820.1)
- jointcommissionjournal.com (https://jointcommissionjournal.com)
- greenlight.guru (https://greenlight.guru/blog/fda-voluntary-improvement-program)
- federalregister.gov (https://federalregister.gov/documents/2024/03/07/2024-04834/q2r2-validation-of-analytical-procedures-and-q14-analytical-procedure-development-international)
- celegence.com (https://celegence.com/harmonizing-iso-149712019-fda-qmsr-medical-device-safety)
- ecfr.gov (https://ecfr.gov/current/title-21/chapter-I/subchapter-F/part-600/subpart-B/section-600.14)
- fda.gov (https://fda.gov/medical-devices/postmarket-requirements-devices/quality-system-qs-regulationmedical-device-current-good-manufacturing-practices-cgmp)
- greenlight.guru (https://greenlight.guru/blog/iq-oq-pq-process-validation)
- Common Challenges and Best Practices for IDE Compliance
- fda.gov (https://fda.gov/news-events/press-announcements/fda-roundup-november-21-2023)
- raps.org (https://raps.org/News-and-Articles/News-Articles/2024/6/Stakeholders-request-elaboration,-consistency-in-F?utm_campaign=regulatory-focus&utm_source=twitter&utm_medium=social)
- ncats.nih.gov (https://ncats.nih.gov/research/research-resources/clinical-research-toolbox?utm_source=X&utm_medium=Social&utm_campaign=Research-Resources-Clinical)
- fda.gov (https://fda.gov/news-events/fda-voices/increasing-options-clinical-research-facilitate-medical-product-development)
- fda.gov (https://fda.gov/regulatory-information/search-fda-guidance-documents/communications-firms-health-care-providers-regarding-scientific-information-unapproved-uses)
- ecfr.gov (https://ecfr.gov/current/title-21/chapter-I/subchapter-D/part-316/subpart-A)
- sonarsource.com (https://sonarsource.com/resources/m-t-bank)
- dev.to (https://dev.to/eugeneo_17/case-study-tdd-in-nodejs-inspector-server-and-other-projects-30e6)
- jetbrains.com (https://jetbrains.com/company/customers/experience/scieneers?utm_campaign=pycharm&utm_medium=social&utm_source=twitter)
- thefdalawblog.com (https://thefdalawblog.com/2024/06/knock-knock-fda-issues-guidance-on-best-processes-and-practices-during-bimo-inspections?utm_source=rss&utm_medium=rss&utm_campaign=knock-knock-fda-issues-guidance-on-best-processes-and-practices-during-bimo-inspections)
- fda.gov (https://fda.gov/drugs/news-events-human-drugs/ich-m12-drug-drug-interaction-studies-final-guidance-10092024)
- greenlight.guru (https://greenlight.guru/blog/how-to-set-up-clinical-studies-to-comply-with-us-fda-regulations)
